Home Cart Sign in  
Chemical Structure| 112522-64-2 Chemical Structure| 112522-64-2

Structure of Tacedinaline
CAS No.: 112522-64-2

Chemical Structure| 112522-64-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

CI-994 is an inhibitor of HDAC1 with IC50 of 0.57 μM with anti-tumor effect. It can cause G1 cell cycle arrest.

Synonyms: N-acetyldinaline; CI-994; CI994, CI-994, CI 994, PD123654, PD-123654, PD 123654, Tacedinaline, acetyldinaline

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Roth, Lukas ; Gotsbacher, Michael P. ; Codd, Rachel ;

Abstract: Immobilized metal-ion affinity chromatog. (IMAC) used to purify recombinant proteins features a resin-bound 1:1 Ni(II)-iminodiacetic acid (IDA) complex. This hemi-saturated Ni(II)-IDA system containing exchangeable sites at the metal ion is re-cast as a surrogate of a coordinatively-unsaturated metalloenzyme active site, with utility for selecting compounds with metal-binding groups from mixtures as potential metalloenzyme inhibitors. Exchanging Ni(II) for other metal ions could broaden the scope of metalloenzyme target. This work examined the performance of Cu(II)-, Fe(III)-, Ga(III)-, Ni(II)-, or Zn(II)-IMAC resins to reversibly bind exptl. or clin. metalloenzyme inhibitors of Zn(II)-ACE1, Zn(II)-HDAC, Fe(II)/(III)-5-LO or Cu(II)-tyrosinase from a curated mixture (1-17). Each IMAC system gave a distinct selection profile. The Zn(II)-IMAC system selectively bound the thiol-containing Zn(II)-ACE1 inhibitors captopril and omapatrilat, and the Fe(III)-IMAC system selectively bound the Fe(II)/(III)-5-LO inhibitor licofelone, demonstrating a remarkable IMAC-metalloenzyme metal ion match. IMAC provides a simple, water-compatible platform, which could accelerate metalloenzyme inhibitor discovery.

Purchased from AmBeed: ; ; ; 76420-72-9 ;

Alternative Products

Product Details of Tacedinaline

CAS No. :112522-64-2
Formula : C15H15N3O2
M.W : 269.30
SMILES Code : O=C(NC1=CC=CC=C1N)C2=CC=C(NC(C)=O)C=C2
Synonyms :
N-acetyldinaline; CI-994; CI994, CI-994, CI 994, PD123654, PD-123654, PD 123654, Tacedinaline, acetyldinaline
MDL No. :MFCD00866266
InChI Key :VAZAPHZUAVEOMC-UHFFFAOYSA-N
Pubchem ID :2746

Safety of Tacedinaline

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H319
Precautionary Statements:P305+P351+P338

Related Pathways of Tacedinaline

epigenetics

Isoform Comparison

Biological Activity

Target
  • HDAC3

    HDAC3, IC50:1.2 μM

  • HDAC2

    HDAC2, IC50:0.9 μM

  • HDAC1

    HDAC1, IC50:0.9 μM

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00004861 Pancreatic Cancer Phase 2 Completed - United States, California ... More >> Cedars-Sinai Comprehensive Cancer Center Los Angeles, California, United States, 90048 United States, Florida H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 United States, Maryland Sinai Hospital of Baltimore Baltimore, Maryland, United States, 21225 United States, Michigan William Beaumont Hospital Royal Oak, Michigan, United States, 48073 United States, North Carolina Raleigh Hematology/Oncology Associates - Wake Practice Raleigh, North Carolina, United States, 27609 United States, Ohio Jewish Hospital of Cincinnati, Inc. Cincinnati, Ohio, United States, 45236 Ireland Cancer Center Cleveland, Ohio, United States, 44106-5065 United States, Tennessee West Clinic, P.C. Memphis, Tennessee, United States, 38117 Sarah Cannon-Minnie Pearl Cancer Center Nashville, Tennessee, United States, 37203 United States, Texas Tyler Cancer Center Tyler, Texas, United States, 75702 United States, Virginia Northern Virginia Oncology Group Fairfax, Virginia, United States, 22031 Canada, Manitoba St. Boniface General Hospital Winnipeg, Manitoba, Canada, R2H 2A6 Canada, Nova Scotia Nova Scotia Cancer Centre Halifax, Nova Scotia, Canada, B3H 1V7 Canada, Ontario Cancer Care Ontario-London Regional Cancer Centre London, Ontario, Canada, N6A 4L6 Ottawa Regional Cancer Center - General Division Ottawa, Ontario, Canada, K1H 8L6 Canada, Quebec Centre Hospitalier de l'Universite de Montreal Montreal, Quebec, Canada, H2L-4M1 Less <<
NCT00005093 Lung Cancer Phase 3 Completed - United States, California ... More >> Cedars-Sinai Comprehensive Cancer Center Los Angeles, California, United States, 90048 United States, Florida H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 United States, Massachusetts New England Medical Center Hospital Boston, Massachusetts, United States, 02111 United States, Michigan University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States, 48109-0752 Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States, 48201 United States, North Carolina Raleigh Hematology/Oncology Associates - Wake Practice Raleigh, North Carolina, United States, 27609 United States, Ohio Arthur G. James Cancer Hospital - Ohio State University Columbus, Ohio, United States, 43210 United States, Tennessee West Clinic, P.C. Memphis, Tennessee, United States, 38117 United States, Texas Southwest Regional Cancer Center Austin, Texas, United States, 78705 Canada, Alberta Cross Cancer Institute Edmonton, Alberta, Canada, T6G 1Z2 Canada, British Columbia British Columbia Cancer Agency - Fraser Valley Cancer Centre Surrey, British Columbia, Canada, V3V 1Z2 BC Cancer Agency Vancouver, British Columbia, Canada, V5Z 4E6 British Columbia Cancer Agency - Vancouver Island Cancer Centre Victoria, British Columbia, Canada, V8R 1J8 Canada, Ontario Ottawa Regional Cancer Center - General Division Ottawa, Ontario, Canada, K1H 8L6 Mount Sinai Hospital - Toronto Toronto, Ontario, Canada, M5G 1X5 Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Less <<
NCT00005624 Multiple Myeloma PHASE2 COMPLETED 2025-02-03 H. Lee Moffitt Cancer Center a... More >>nd Research Institute, Tampa, Florida, 33612, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.71mL

0.74mL

0.37mL

18.57mL

3.71mL

1.86mL

37.13mL

7.43mL

3.71mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories